沛嘉医疗(09996.HK) 宣布,用于治疗重度主动脉瓣反流的Trilogy经导管心脏瓣膜系统,已于台湾完成首两例植入。(gc/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.